| ACG | American College of Gastroenterology |
| AGA | American Gastroenterological Association |
| AISP | Italian Association for the Study of the Pancreas |
| ASCO | American Society of Clinical Oncology |
| AT | Ataxia–Telangiectasia |
| BD-IPMN | Branch-Duct IPMN |
| BER | Base Excision Repair |
| CAPS | International Cancer of the Pancreas Screening |
| CDKN2A | Cyclin-Dependent Kinase Inhibitor 2A |
| CFTR | Cystic Fibrosis Transmembrane Conductance Regulator |
| CI | Confidence Interval |
| CR | Complete Response |
| CT | Computed tomography |
| DDR | DNA Damage Repair |
| dMMR | Mismatch Repair Protein Deficiency |
| DPCA | Dutch Pancreatic Cancer Audit |
| DSB | Double-Strand Break |
| EUROPAC | European Registry of Hereditary Pancreatitis and Pancreatic Cancer |
| EUS | Endoscopic Ultrasonography |
| FAMM | Familial Atypical Multiple Mole Melanoma |
| FAP | Familial Adenomatous Polyposis |
| FNA | Fine-Needle Aspiration |
| FNB | Fine-Needle Biopsy |
| FPC | Familial Pancreatic Cancer |
| GenoMEL | Melanoma Genetics Consortium |
| HBOC | Hereditary Breast and Ovarian Cancer |
| HP | Hereditary Pancreatitis |
| HPC | Hereditary Pancreatic Cancer |
| HR | Homologous Recombination |
| HRD | Homologous Recombination Deficiency |
| HRHR | Homologous Recombination |
| HRI | High-Risk Individual |
| ICI | Immune Checkpoint Inhibitor |
| IPMN | Intraductal Papillary Mucinous Neoplasm |
| IRFARPC | Italian Registry of Families At Risk of Pancreatic Cancer |
| LAPCR | Locally Advanced Pancreatic Cancer Registry |
| LFS | Li–Fraumeni Syndrome |
| LS | Lynch Syndrome |
| MD-IPMN | Main Duct-IPMN |
| MLH1 | MutL Homolog 1 |
| MMR | Mismatch Repair |
| MRCP | Magnetic Resonance Cholangiopancreatography |
| MRI | Magnetic Resonance Imaging |
| MSH2 | MutS Homolog 2 |
| MSH6 | MutS Homolog 6 |
| MSI | Microsatellite Instability |
| MSI-H | MSI-High |
| MSI-I | MSI-Indeterminate |
| MSS | Microsatellite Stable |
| NCCN | National Comprehensive Cancer Network |
| NCR | Netherlands Cancer Registry |
| OGV | Pathogenic Germline Variant |
| ORR | Objective Response Rate |
| OS | Overall Survival |
| PANGENFAM | Spanish Familial Pancreatic Cancer Registry |
| PanIN | Pancreatic Intraepithelial Neoplasia |
| PARPi | Poly-(ADP-ribose) Polymerase inhibitor |
| PC | Pancreatic Cancer |
| PFS | Progression-Free Survival |
| PGPV | Presumed Germline Pathogenic Variant |
| PGV | Pathogenic Germline Variants |
| PJS | Peutz–Jeghers Syndrome |
| PMS-2 | Post-Meiotic Segregation increased 2 |
| PRECEDE | Pancreatic Cancer Early Detection Consortium |
| PRSS1 | Protease Serine 1 |
| RER+ | Replication Error—positive |
| RR | Relative Risk |
| SEER | Surveillance, Epidemiology, and End Results |
| SPINK1 | Serine Protease Inhibitor Kazal type 1 |
| SSB | Single-Strand Breaks |
| STK11 | Serine/Threonine Kinase 11 |
| TMN | Tumor Mutational Burden |